Log inSign up
Reading a stock page
  • The tabs show the price chart, results, shareholding, events and news for this one company.
  • The Signal Score sums up trend, momentum and quality from past data. It is a description, not a forecast.
  • Every figure names its source. "Official" means it came from NSE or BSE filings.
  • Use the star to watch the stock, or Add to portfolio to record a trade.

Prices during market hours are delayed by up to 15 minutes. Nothing here is a recommendation to buy or sell.

« Dashboard

AARTIPHARM ☆ BSE also on NSE

Aarti Pharmalabs Limited · code 543748 · INE0LRU01027 · Pharma & Healthcare · series A · Daily price history

989.80 -35.00 (-3.42%) close on 20 Nov 2026
Official NSE & BSE Auto-Sync: Checking Overview, Financials, Technicals, Shareholding & Events in the background...
79

ISA Signal Score: Strong setup

Buy candidate: research it further. Based on prices to 2026-11-20. Confidence 100%.

Trend100
Momentum84
52-week range92
Volume83
Risk56
Fundamentals60

Working for it

  • Price is above its 20-day average
  • Price is above its 50-day average
  • Price is above its 200-day average (long-term uptrend)
  • 50-day average is above the 200-day average
  • 50-day average is rising
  • RSI 59: healthy strength

Working against it

  • Revenue fell 5% year on year

Measured reference levels (not forecasts): 20-day low 821.05, 52-week high 1,024.80, typical daily move 41.95, two typical moves below price 905.91.

A rule-based reading of price, volume and filed numbers. It is information, not investment advice, and it can be wrong. Do your own research.

At a glance

Five quick readings from results and prices. A starting point for your own research, not advice.
QualityAverageROE 13.1%, ROCE 18.0%, debt 0.15x equity
GrowthNot knownNeeds at least 3 years of results. More years load on later visits.
ValuationCheapP/E 41.4 vs sector median 53.0, 5.1x book
MomentumStrongAbove its 200-day average, beat NIFTY 50 by 40.4 points
RiskHighSwings 47% a year, fell up to 27% from a peak, beta 1.13

Smart Investor Tips: AARTIPHARM

Constructive Setup (Trend + Fundamentals Aligned)

Actionable Insights & Positives

  • Confirmed uptrend: trading above both rising 50-day (Rs 902.19) and 200-day (Rs 761.56) averages.
  • Attractive relative valuation: P/E of 41.4x is at a discount to the sector median of 53.0x.
  • Tip: Click the star button above to add this stock to your Watchlist and set a target "Buy below" alert price.

Risk Checks & Things to Verify

  • High 30-day annualized volatility (55%). Keep initial position sizes smaller and use wider stop-review levels.

BSE Authentic Bhavcopy & Cross-Exchange Check No API Key

Runs authentic BSE price & volume verification (latest BSE Bhavcopy snapshot, split-adjusted 52W High/Low, 20/50/200 DMA alignment, and 20-day volume trend, plus cross-listed NSE MCP check when shared by ISIN).

Algorithmic Momentum Prediction & Optimal Entry PriceBUY / POSITIVE IN ZONE (Score 85/100)

Strong technical, volume & cash-flow setup. Best support area: Rs 888.66 – Rs 979.90 (Ideal entry ~Rs 934.28). Stagger 50% near Rs 979.90 and 50% near Rs 888.66. Risk level / review below Rs 705.16; Swing Target Rs 1,346.70 (R:R 1.8x).

Optimal Support areaTranche 1 (50%)Tranche 2 (50%)Risk level / ReviewLevel 1 (Swing)Level 2 (Breakout)Risk : Reward
Rs 888.66 – Rs 979.90
Ideal ~Rs 934.28
Rs 979.90 Rs 888.66 Rs 705.16
ATR 4.2%
Rs 1,346.70 Rs 1,621.64 1 : 1.8
RSI 72 · Vol 1.92x
1M 3M 6M 1Y 3Y ALL Investment checklist Download CSV 3M change +18.6% · high 1,047.90 · low 765.00 · max drawdown -15.8%

Live Candlestick & TradingView Chart (AARTIPHARM)

MARKET CLOSED - EOD SNAPSHOT
Style:  Timeframe:  Overlays:

Key figures results FY24, price 20 Nov

P/E41.4sector median 53.0
P/B5.10xprice / book value
EPSRs 23.93grew 12.1% a year
Dividend yield-from saved dividend events
Debt to equity0.15xnet debt Rs 240 Cr
Sales growth-4.8%a year over 1 years
Profit growth11.9%a year over 1 years
Operating margin20.8%net margin 11.7%

From the official NSE results filings, consolidated. P/E uses the last full year's EPS, PEG 3.49, EV/EBITDA 23.9. See all years.

Company Debt, Borrowings & Cash Flow Health (Official FY24 Consolidated Filing)

Auto-extracted from official NSE/BSE XBRL Balance Sheet & Cash Flow statements (Rs Crore).

Strong Balance Sheet & Cash Flow · Score 93/100
Total Debt / Loans Rs 264 Cr Increased +Rs 50.1 Cr YoY
Cash & Bank Balances Rs 24.1 Cr Liquid cash & equivalents
Net Debt (Loans − Cash) Rs 240 Cr 10.2% of total assets
Debt to Equity & Interest Cover 0.15x D/E Interest cover: 18.5x EBIT
Operating Cash Flow (OCF) Rs 216 Cr OCF/PAT conversion: 100%
Free Cash Flow (FCF) Rs 60.8 Cr After Capex of Rs 156 Cr
  • Low Debt-to-Equity (0.15x).
  • Strong loan interest coverage (18.5x EBIT/Interest).
  • High earnings quality: Operating Cash Flow converts 117% of net profit into real cash.
  • Positive Free Cash Flow (Rs 60.8 Cr after Capex) available for debt reduction & dividends.

About Aarti Pharmalabs

No company description saved yet. Use Profile below to read about this company.

Listed on BSE NSE

Market capNot available
First listed30 Jan 2023BSE not available · NSE 30 Jan 2023
Face valueRs 5
Book valueNot available
ROENot availableReturn on equity
ROCENot availableReturn on capital employed

NSE: listing date, face value

Profile completeness2 of 8Missing: description, industry, share count, book value, ROE, ROCE

Not checked yet.

Profile, History and Financial records open a web search for this company in a new tab.

Shareholding

Promoters and group 39.66% -3.20 pp, public 60.34%, as on 30 Sep 2026. Holder names and history

Day range986.00 to 1,028.30Open 1,025.60
52-week high1,047.90 -5.5% from high (19 Nov 2026)
52-week low583.85 +69.5% from low (30 Mar 2026)
Volume24,935 0.6x the 20-day average
RSI (14)59 neutral
Volatility (30d)55.4%annualised
583.85
1,047.90

Returns

1W-1.0%
1M+17.6%
3M+21.2%
6M+38.5%
1Y+38.9%
YTD+31.6%
3Y a year+34.7%

Against the NIFTY 50

PeriodAARTIPHARMNIFTY 50Difference
1M+17.6%+13.1% +4.5 pts
3M+21.2%+6.4% +14.8 pts
6M+38.5%+8.8% +29.8 pts
1Y+38.9%-1.5% +40.4 pts

Risk over the past year

Volatility47%high
Deepest fall-26.7%from a peak
Beta1.13moves with the index
Best day+20.0%10 Aug 2026
Worst day-7.8%08 Oct 2026
Up days51%of sessions

Returns use closing prices. Bonus issues and splits are adjusted automatically when detected. Beta compares daily moves with the NIFTY 50 over 246 shared sessions.

AI analysis

Company turnover, products, risks and entry ideas, written by the AI provider you set up in Settings.

Open AI analysis

🛡 Forensic Financial Health: Piotroski F-Score & 3-Step DuPont ROE Decomposition

Institutional balance-sheet quality, earnings-to-cash conversion, and ROE driver breakdown from official XBRL filings.

Piotroski F-Score: 6 / 9 · Solid Financial Health
3-Step DuPont ROE Identity: Balanced Profitability & Efficiency
Net Margin: 11.7% × Asset Turnover: 0.72x × Equity Multiplier: 1.47x = ROE 13.1%
✓ Positive Net Profit (PAT > 0) Rs 216 Cr
✓ Positive Operating Cash Flow (OCF > 0) Rs 216 Cr
✓ High Cash Conversion (OCF >= 85% of PAT) 100% conversion
⚠ Improving Return on Assets (ROA YoY) 8.4% vs 8.7%
✓ Conservative / Decreasing Debt-to-Equity 0.15x (prev 0.14x)
✓ Healthy Balance Sheet Asset Coverage 3.72x
⚠ Institutional Return on Equity (ROE >= 14%) 13.1%
✓ Stable / Expanding Profit Margin YoY 11.7% vs 9.9%
⚠ Asset Turnover Efficiency (Sales / Assets) 0.72x

Quarterly Results (Last 8 Quarters — QoQ & YoY Acceleration) Rs crore

Rs crore Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026 Sep 2026
Sales / Revenue 538564386418432583536610
Sales QoQ % +17.5%+4.8%-31.6%+8.3%+3.3%+35.0%-8.1%+13.8%
Operating Profit 12914793.075.0103113136136
Operating Margin (OPM %) 24.0%26.1%24.1%17.9%23.8%19.4%25.4%22.3%
Net Profit (PAT) 74.088.050.028.048.061.076.071.0
Profit QoQ % +34.5%+18.9%-43.2%-44.0%+71.4%+27.1%+24.6%-6.6%
Profit YoY % +39.6%+35.4%-9.1%-49.1%-35.1%-30.7%+52.0%+153.6%
Net Margin % 13.8%15.6%13.0%6.7%11.1%10.5%14.2%11.6%

Sales and profit Rs crore, consolidated

Sales growth-4.8%a year, 1Y
Profit growth+11.9%a year, 1Y
EPS growth+12.1%a year, 1Y
Avg ROE12.7%2 years

Profit and loss

Rs croreFY23FY24
Sales1,9451,853
Sales growth--4.8%
Operating profit342386
Operating margin17.6%20.8%
Other income2.324.90
Interest21.117.2
Depreciation62.573.2
Profit before tax261300
Tax rate25.8%27.8%
Net profit193216
Profit growth-+11.9%
Net margin9.9%11.7%
EPS (Rs)21.3523.93

Balance sheet

Rs croreFY23FY24
Equity (net worth)1,5581,757
Borrowings214264
Cash25.024.1
Total assets2,2312,582
Debt to equity0.14x0.15x

Debt, Loans, Cash Flow & Working Capital

Rs croreFY23FY24
Operating Cash Flow (OCF)263216
Capital Expenditure (Capex)120156
Free Cash Flow (FCF = OCF - Capex)14360.8
OCF / Net Profit Conversion1.36x1.00x
Total Borrowings / Loans214264
Cash & Bank Balances25.024.1
Trade Receivables (Cr)440519
Receivable Days82.57x102.32x
Inventories (Cr)602643
Inventory Days112.97x126.66x

Returns on capital

Rs croreFY23FY24
ROE12.4%13.1%
ROCE17.2%18.0%
Interest cover13.39x18.46x

Read from the official annual results filed with NSE (XBRL), consolidated figures. ROE uses average equity of the year and the year before when both are saved, ROCE uses profit before interest and tax over total assets less current liabilities. EPS is per today's share. Check the annual report before investing.

Compared with its sector Pharma & Healthcare

StockPriceDay1 yearMkt cap (Cr)P/EP/BROENet margin
LAURUSLABSLaurus Labs Limited 2,295.00 -0.3% - 123,689 139.4 23.3 16.8% 13.1%
ZYDUSLIFEZydus Lifesciences Limited 1,195.05 -0.4% - 120,222 31.3 6.1 0.6% 0.6%
GLENMARKGLENMARK PHARMACEUTICALS LTD. 2,648.00 +1.0% - 74,724 - 9.5 -19.1% -12.7%
FORTISFORTIS HEALTHCARE LTD. 825.00 +2.0% - 62,284 59.8 - 7.8% 11.7%
GLANDGland Pharma Limited 3,331.35 +1.2% - 54,871 53.4 - 8.9% 16.0%
GLAXOGLAXOSMITHKLINE PHARMACEUTICAL 2,732.50 +0.7% - 46,291 78.5 26.0 33.2% 17.1%
EMCUREEmcure Pharmaceuticals Limited 2,336.05 -0.4% - 44,317 47.9 9.0 19.0% 10.2%
SAILIFESai Life Sciences Limited 1,800.35 +0.7% - 38,243 109.2 15.4 14.0% 15.9%
WOCKPHARMAWOCKHARDT LTD. 2,183.10 -0.2% - 33,620 166.4 6.8 4.3% 6.4%
GRANULESGRANULES INDIA LTD. 823.70 +2.4% - 19,964 34.3 3.9 11.7% 11.1%
ERISEris Lifesciences Limited 1,319.50 -0.6% - 17,949 45.8 6.9 15.2% 19.5%
ALIVUSALIVUS LIFE SCIENCES LIMITED 1,434.15 -1.1% - 17,576 37.3 7.5 20.2% 20.6%
AARTIPHARMAarti Pharmalabs Limited 989.80 -3.4% - 8,970 41.4 5.1 12.3% 11.7%
Sector median- 53.09.012.8%

The 13 largest of 80 stocks in this sector on BSE, by market cap where known and traded value otherwise. Valuation shows for stocks whose results this site has read; it fills in as people open more stock pages. Prices from 20 Nov 2026.

Today: 15 minute chart and signal

Opens when you view this tab.

Analysis and next-session reading

Opens when you view this tab.

Complete analysis report Financials, shareholding, events, risks and a data reliability score.

Signals

Price is above its 50-day average 20-day average is above the 50-day (short-term uptrend) Price is above its 200-day average (long-term uptrend) RSI 59: neutral

Simple rules applied to end-of-day prices. They describe what the chart is doing and are not advice to buy or sell.

When is a good price? from this stock's own price history

The price is in the upper quarter of its 1-year range and is lower than it was on 2% of days in the past year.

Support (prices below today's)

50-day average902.19-8.9%
20-day low782.50-20.9%
60-day low765.00-22.7%
200-day average761.56-23.1%
52-week low583.85-41.0%

Resistance (prices above today's)

20-day high1,047.90+5.9%
60-day high1,047.90+5.9%
52-week high1,047.90+5.9%

Zones buyers often watch

Lower quarter of the 1-year range 583.85 to 699.86 Historically the cheapest part of the past year.
Pullback of 10% to 20% from the high 838.32 to 943.11 A common area for dips inside an uptrend.
Around the 200-day average 738.71 to 784.40 Long-term trend line, often watched as support.

Deepest fall from a peak in the past year: -26.7%. Currently -3.4% below its latest peak. Levels are from history and do not predict where the price will go.

Moving averages and momentum

IndicatorValueReading
20-day average934.25 Price is 5.9% above
50-day average902.19 Price is 9.7% above
200-day average761.56 Price is 30.0% above
RSI (14)59Neutral
MACD (12, 26, 9)34.93Above its signal line (momentum rising)
Volatility (30d)55.4%High yearly swings

Support and resistance

R21,043.67
R11,016.73
Pivot1,001.37
S1974.43
S2959.07

Classic pivot levels from the latest session's high, low and close. Prices often pause near them, but they are only reference points.

DateOpenHighLow CloseChangeVolume
2026-11-20 1,025.60 1,028.30 986.00 989.80 -3.42% 24,935
2026-11-19 1,047.90 1,047.90 991.45 1,024.80 +1.31% 34,870
2026-11-18 1,016.40 1,024.75 992.05 1,011.55 -0.48% 37,968
2026-11-17 999.00 1,046.95 980.20 1,016.40 +3.06% 83,291
2026-11-16 999.50 1,024.65 980.30 986.25 -1.31% 71,320
2026-11-13 1,013.30 1,019.95 989.95 999.35 -0.96% 35,745
2026-11-12 932.15 1,018.45 932.15 1,009.00 +9.12% 75,187
2026-11-11 936.45 940.70 920.00 924.70 +0.54% 28,961
2026-11-09 929.30 959.50 914.75 919.70 -1.23% 30,427
2026-11-06 920.00 932.95 900.00 928.95 +0.05% 31,353
2026-11-05 940.00 946.05 917.60 928.50 +0.19% 26,322
2026-11-04 928.00 934.20 912.90 926.75 +0.78% 25,156
2026-11-03 887.95 931.00 887.95 919.60 +3.34% 36,462
2026-11-02 873.65 898.95 869.50 889.90 +1.86% 15,231
2026-10-30 938.00 938.00 864.55 873.65 -5.81% 38,275
2026-10-29 900.45 969.10 856.05 927.55 +5.44% 167,668
2026-10-28 893.95 899.00 870.00 879.70 -0.59% 15,836
2026-10-27 834.60 889.90 817.55 884.90 +7.53% 39,464
2026-10-26 821.10 842.95 814.85 822.90 +0.23% 17,212
2026-10-23 819.40 825.05 782.50 821.05 -0.96% 48,512
2026-10-22 830.00 843.25 820.10 829.05 -1.51% 23,290
2026-10-21 842.80 852.20 827.10 841.80 +0.95% 52,315
2026-10-19 878.05 878.05 831.40 833.85 -4.72% 34,697
2026-10-16 869.90 888.05 865.00 875.15 +1.39% 11,091
2026-10-15 867.25 869.75 858.45 863.15 -0.38% 12,786
2026-10-14 885.50 885.50 848.00 866.40 -2.04% 27,802
2026-10-13 878.10 887.95 845.10 884.40 +0.72% 47,071
2026-10-12 864.00 890.00 861.55 878.10 +2.59% 23,718
2026-10-09 879.75 890.80 851.10 855.90 -2.67% 45,044
2026-10-08 956.00 956.00 875.80 879.35 -7.76% 54,009
2026-10-07 981.50 981.50 950.00 953.35 -2.19% 28,972
2026-10-06 960.00 986.55 955.65 974.65 +2.92% 61,360
2026-10-05 983.70 989.00 942.15 947.00 -2.00% 46,694
2026-10-01 953.00 985.00 922.00 966.30 +1.48% 28,063
2026-09-30 991.55 1,001.55 944.75 952.25 -2.16% 70,927
2026-09-29 912.00 983.50 908.85 973.30 +6.49% 54,153
2026-09-28 943.35 946.75 911.30 914.00 -2.66% 40,967
2026-09-25 933.95 962.00 914.90 938.95 +0.48% 47,746
2026-09-24 930.00 956.65 924.45 934.45 -0.60% 47,828
2026-09-23 885.20 957.00 885.20 940.10 +6.40% 126,376
2026-09-22 846.75 909.00 846.75 883.55 +4.38% 120,883
2026-09-21 820.00 870.65 814.10 846.45 +3.12% 72,640
2026-09-18 827.85 845.00 813.00 820.85 +0.27% 279,991
2026-09-17 817.55 833.95 804.05 818.65 +0.71% 45,206
2026-09-16 789.30 818.70 765.00 812.85 +2.98% 30,916
2026-09-15 832.90 833.80 787.05 789.30 -4.77% 27,274
2026-09-11 827.00 833.10 814.50 828.85 +0.47% 20,515
2026-09-10 836.00 838.00 814.85 825.00 -0.57% 15,109
2026-09-09 863.85 872.05 820.60 829.75 -4.36% 39,762
2026-09-08 867.75 889.25 862.00 867.60 +0.68% 33,326
2026-09-07 859.05 894.00 856.50 861.70 +0.20% 47,560
2026-09-04 870.35 879.50 854.85 860.00 -0.69% 20,036
2026-09-03 867.75 885.00 856.85 865.95 -0.21% 29,339
2026-09-02 865.20 878.50 862.60 867.75 +0.27% 26,927
2026-09-01 845.00 873.85 836.00 865.45 +2.48% 22,499
2026-08-31 842.85 863.70 830.00 844.50 +0.60% 28,367
2026-08-28 814.45 844.00 814.45 839.50 +3.10% 12,863
2026-08-27 832.15 843.55 811.00 814.25 -2.78% 34,804
2026-08-26 835.00 862.50 832.60 837.50 +0.28% 27,602
2026-08-25 846.85 848.20 830.35 835.15 -1.01% 9,841
2026-08-24 816.95 859.55 809.00 843.65 +3.31% 31,668
2026-08-21 825.75 837.70 807.75 816.60 -1.53% 25,300
2026-08-20 834.00 848.00 823.65 829.30 -0.65% 11,289
2026-08-19 879.95 883.55 827.30 834.70 -4.26% 15,179

News from the last 15 days More

Shareholding pattern

Up to dateNSE listingChecks passed

Quarter ended 30 Sep 2026, filed 17 Oct 2026. Latest filing is for the expected quarter (Sep 2026). Company: Aarti Pharmalabs Limited, ISIN INE0LRU01027.

Promoters and group
39.66%
-3.20 pp vs Jun 2026
Public (all, Category B)
60.34%
+3.20 pp vs Jun 2026

Foreign, domestic institution and mutual fund lines need the filing file for the period. An admin can load them under Admin > Shareholding tracker.

Ownership split

Trend

Latest quarter compared

CategoryPrevious (Jun 26)Latest (Sep 26)Change (pp)Change in sharesYear earlier (pp)What it may mean
Promoters and group42.86%39.66%-3.20 pp--3.22 ppPromoter holding fell. A change alone is not a sell or buy signal. Check the filing for the reason (market sale, transfer inside the group, new issue).
Public (all, Category B)57.14%60.34%+3.20 pp-+3.22 ppPublic holding rose. This is the mirror of promoter and other changes. It does not show what retail investors did.

Change is in percentage points (latest percent minus previous percent), not a relative change. Mutual funds and insurers are part of domestic institutions and are never added to it. Only comparable quarters (1 to 6 months apart; about a year for the year-earlier column) are compared.

Insights and risk alerts

Moderate Promoter holding decreased Jun 2026 to Sep 2026

Promoter ownership fell from 42.86% to 39.66%, a decline of 3.20 percentage points.

Rule: Rule P1: promoter holding moved by at least 1 percentage points between comparable quarters.

Limits: May come from promoter transactions, new share issues, a buyback, a transfer inside the group, or re-classification. It does not by itself make the outlook better or worse.

Check next: Open the filing and the company announcements for the reason. Compare the share count.

Moderate Promoters and group: 3 quarters in a row lower Dec 2025 to Sep 2026

A steady move is more informative than one quarter, but it still only describes reported ownership.

Rule: Rule T1: the same direction for 3 consecutive quarters, with a combined move of at least 1 percentage points.

Limits: Persistent dilution through share issues can look the same.

Check next: Look at share capital changes and corporate actions in these quarters.

These alerts describe reported ownership. They are not buy or sell advice. Judge the company with its results, debt, valuation and announcements.

Who holds the shares

Largest holders named in the Sep 2026 filing.

NameTypeShares% of companyLocked-in shares
Life Insurance Corporation Of IndiaInsurance Companies42,82,4524.72% -
Rashesh Chandrakant GogriIndividuals Or HUF38,34,4044.23% -
Jaya Chandrakant GogriIndividuals Or HUF32,04,3103.53% -
Anushakti Enterprise Private LimitedBodies Corporate29,92,9503.30% -
LABDHI BUSINESS TRUST(Saswat Trusteeship Private Limited)Trusts28,41,5043.13% -
Hetal Gogri GalaIndividuals Or HUF28,15,6123.11% -

Quarter by quarter

Quarter endedPromotersChangePublicChangeFiledSource
Sep 202639.66%-3.20 pp60.34%+3.20 pp17 Oct 2026
Jun 202642.86%-0.22 pp57.14%+0.22 pp16 Jul 2026
Mar 2026 revised43.08%-0.02 pp56.92%+0.02 pp16 Apr 2026
Dec 202543.10%+0.22 pp56.90%-0.22 pp16 Jan 2026
Sep 202542.88%-0.84 pp57.12%+0.84 pp16 Oct 2025
Jun 2025 revised43.72%-0.57 pp56.28%+0.57 pp18 Jul 2025
Mar 202544.29%-0.37 pp55.71%+0.37 pp11 Apr 2025NSE
Dec 202444.66%-1.44 pp55.34%+1.44 pp14 Jan 2025NSE
Sep 202446.10%-0.36 pp53.90%+0.36 pp11 Oct 2024NSE
Jun 202446.46%0.00 pp53.54%0.00 pp17 Jul 2024NSE
Mar 202446.46%0.00 pp53.54%0.00 pp12 Apr 2024NSE
Dec 202346.46%+0.16 pp53.54%-0.16 pp10 Jan 2024NSE
Sep 202346.30%+0.32 pp53.70%-0.32 pp09 Oct 2023NSE
Jun 202345.98%0.00 pp54.02%0.00 pp13 Jul 2023NSE
Mar 202345.98%+1.82 pp54.02%-1.82 pp19 Apr 2023NSE
Jan 202344.16%-55.84%-31 Mar 2023NSE
Shareholding details

Loading...

Events

Not checked yet

BSE events come from the BSE corporate actions file, which an admin uploads. There is no automatic BSE fetch. Nothing has been imported for this stock yet.

No events saved for this stock yet.

Fetched from NSE automatically and saved on this site, so past events stay available. Ex date is the first day the stock trades without the benefit; a bonus or split is applied to old prices on its own from that day. Confirm on the exchange website before acting.

ISA shows information and signals worked out from past prices and company filings. They are not recommendations to buy, sell or hold any security, and ISA is not a SEBI-registered investment adviser or research analyst. Prices may be delayed. Check with a registered adviser before you invest.